Predicting Clinical Outcomes in Advanced Melanoma Patients Treated With Anti–PD-1 Antibodies
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Pretreatment Metastatic Growth Rate Determines Clinical Outcome of Advanced Melanoma Patients Treated With Anti-PD-1 Antibodies: A Multicenter Cohort Study
J Immunother Cancer 2021 May 01;9(xx)e002350, NB Wagner, MM Lenders, K Kühl, L Reinhardt, F André, M Dudda, N Ring, C Ebel, R Stäger, C Zellweger, R Lang, M Paar, P Gussek, G Richtig, SH Stürmer, S Kimeswenger, A Oellinger, A Forschner, U Leiter, B Weide, M Gassenmaier, A Schraag, B Klumpp, W Hoetzenecker, C Berking, E Richtig, M Ziemer, J Mangana, P Terheyden, C Loquai, VA Nguyen, C Gebhardt, F Meier, S Diem, A Cozzio, L Flatz, M Röcken, C Garbe, TK EigentlerFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.